Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Shuwen Biotech and DiagnoCure Sign Exclusive License and Collaboration Agreement

Published: Saturday, June 07, 2014
Last Updated: Saturday, June 07, 2014
Bookmark and Share
Agreement for commercializing Previstage™ GCC colorectal cancer staging test in China.

Shuwen Biotech Co. Ltd. has announced that it has formed an alliance with the Canada-based DiagnoCure, Inc. to commercialize the Previstage™ GCC colorectal cancer staging test in China.

Under the exclusive license and collaboration agreement, DiagnoCure has granted Shuwen Biotech an exclusive license to commercialize the Previstage™ GCC colorectal cancer staging test in the Greater China Region (China, Hong Kong, and Taiwan).

Shuwen Biotech will conduct clinical trials in China on an IVD kit format of the Previstage™ test, and obtain a regulatory approval from the Chinese FDA for the kit.

Shuwen Biotech will manufacture the IVD kit in its own manufacturing facilities and market the kit to major Chinese hospitals. In addition, Shuwen Biotech will also offer the Previstage™ testing service from its own clinical reference lab.

“Shuwen Biotech is a leading molecular diagnostic company in China led by its Chairman and CEO Jay Z. Zhang, a diagnostic industry veteran, who was formerly a senior vice president at Myriad Genetics. Collaborating with Jay and his team will undoubtedly create value for both corporations and most importantly help colon cancer patients receive the most appropriate treatment,” commented Dr. Yves Fradet, President and Chief Medical Officer of DiagnoCure.

“The ability to collaborate with DiagnoCure and to market Previstage™ GCC in the Greater China Region provides Shuwen with an exciting opportunity. We strongly believe in the benefits of Previstage™ GCC to help in staging and better control of colorectal cancer, a condition afflicting unfortunately a growing number of patients in China,” said Mr. Jay Z. Zhang.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!